Celltrion Takes Aim At US Infliximab Market With Subcutaneous Launch
Korean Firm's Zymfentra Is First And Only SC Version Of Infliximab Approved By The FDA
Celltrion has delivered on its long-awaited US launch of its Zymfentra subcutaneous formulation of infliximab, sold in other territories as Remsima SC.
